Coloplast Strengthens Leadership Structure for Future Growth
Coloplast A/S has announced an expansion of its Executive Leadership Team (ELT) with immediate effect, highlighting the company's commitment to enhancing its strategic direction and operational efficiency.
The decision comes as part of Coloplast's strategy to bolster its business ahead of the final year of its 2025 plan. According to Kristian Villumsen, CEO of Coloplast, this move aligns with their ongoing investments in key business areas that are expected to drive value creation moving forward.
Strategic Focus on Chronic Care
In the newly formed ELT, the Chronic Care division, which encompasses both Innovation and commercial operations, will now be led by Nicolai Buhl, who has been appointed as the Executive Vice President of Chronic Care. This reorganization reflects the importance of focusing leadership on critical business areas that contribute to the company's success.
Villumsen remarked, “Our current strategic efforts have significantly strengthened our innovation capabilities, and we have successfully launched a greater number of products into the market. This next phase is about harnessing the potential of our investments and new innovations in the Chronic Care sector.”
Farewell to a Valued Executive
As part of this organizational change, Paul Marcun, who played a key role in Coloplast's growth over the years, will retire after 36 years in the MedTech industry. Kristian Villumsen expressed gratitude for Marcun's contributions and leadership throughout his tenure at Coloplast.
New Additions to the Executive Leadership Team
Coloplast is also welcoming two new members to its ELT. Caroline Vagner Rosenstand has been appointed as the Executive Vice President for Voice & Respiratory Care, while Thomas Johns Jr. has taken on the role of Executive Vice President for Interventional Urology.
Rosenstand, who has been successfully managing the Voice & Respiratory Care division since the acquisition of Atos Medical, has a track record of building strong teams and delivering impressive growth rates. Meanwhile, Johns Jr. is expected to further accelerate the growth of the Interventional Urology division, leveraging both organic and acquisition strategies.
Investments in Advanced Wound Care
Coloplast is committed to expanding its footprint in the Advanced Wound Care market. The company has invested significantly in both dressings and biologics, with a focus on enhancing profitability. Villumsen stated, "Our strategy is to advance our commercial efforts while ensuring we effectively integrate Kerecis into our operations, with the ambition of becoming a leading player in the biologics category."
Meet the Executive Leadership Team
The new Executive Leadership Team of Coloplast consists of the following members:
- Kristian Villumsen, President and CEO
- Anders Lonning-Skovgaard, Executive Vice President and CFO
- Dorthe Rønnau, Executive Vice President, People & Culture
- Allan Rasmussen, Executive Vice President, Global Operations
- Nicolai Buhl, Executive Vice President, Chronic Care
- Caroline Vagner Rosenstand, Executive Vice President, Voice & Respiratory Care
- Thomas Johns Jr, Executive Vice President, Interventional Urology
This diverse team is poised to steer Coloplast towards achieving its strategic goals, ensuring the organization adapts to shifting market dynamics and continues to deliver innovative solutions in healthcare.
Contact Information
For further details, Coloplast invites investors and media representatives to reach out to:
Investors and Analysts:
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111
Aleksandra Dimovska
Vice President, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: dkadim@coloplast.com
Press and Media:
Peter Mønster
Sr. Media Relations Manager
Tel. +45 4911 2623
Email: dkpete@coloplast.com
Company Address:
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Company reg. (CVR) no. 69749917
Frequently Asked Questions
What prompted the expansion of Coloplast's Executive Leadership Team?
The expansion was initiated to align leadership with the company’s strategic goals as it enters the final stages of its 2025 strategy, focusing on key growth areas.
Who leads the Chronic Care division now?
Nicolai Buhl has been appointed as the Executive Vice President for Chronic Care, overseeing the commercial and innovation efforts in this segment.
What is the significance of the additions to the ELT?
The new members, Caroline Vagner Rosenstand and Thomas Johns Jr., bring extensive experience and leadership to rapidly growing sectors of the business.
How is Coloplast enhancing its position in Advanced Wound Care?
The company is investing in technology and integrating its operations post-acquisition to boost profitability and market presence in advanced wound care solutions.
How can individuals get in touch with Coloplast for more information?
Investor inquiries can be directed to Anders Lonning-Skovgaard or Aleksandra Dimovska, while press inquiries can reach Peter Mønster for further assistance.
